Lv31
252 积分 2025-12-29 加入
Challenges of Cellular Therapy During the COVID-19 Pandemic
5小时前
待确认
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
21天前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
24天前
已完结
Challenges facing CAR T-cell immunotherapy in multiple myeloma
27天前
已完结
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?
27天前
已完结
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
1个月前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
1个月前
已完结
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)
1个月前
已完结
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
1个月前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
1个月前
已完结
皖公网安备34019202002308
